MDxHealth SA Ordinary Shares (MDXH) — Analysis Summary
MDxHealth SA Ordinary Shares (MDXH) has a market cap of $68.84M with year-over-year revenue growth of +19.8%. Net margin stands at -31.1%. The stock trades at a P/E ratio of -2.1.
Key Takeaways
- Revenue changed +19.8% year-over-year
- Net margin of -31.1%
- P/E ratio of -2.1
Compared with its sector, MDXH posted revenue growth of +19.8% and trades at a P/E of -2.1.
MDxHealth SA Ordinary Shares (MDXH)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -18.3x — earnings do not cover interest payments
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin at -13.4% — material operating losses
Net margin at -31.1% — significant losses
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Employees
364
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.